New York State Common Retirement Fund Boosts Stock Position in Grifols, S.A. (NASDAQ:GRFS)

New York State Common Retirement Fund lifted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 38.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,058,286 shares of the biotechnology company’s stock after acquiring an additional 572,439 shares during the period. New York State Common Retirement Fund’s holdings in Grifols were worth $23,794,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Cardinal Capital Management grew its stake in shares of Grifols by 10.4% during the fourth quarter. Cardinal Capital Management now owns 93,616 shares of the biotechnology company’s stock worth $1,082,000 after acquiring an additional 8,789 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Grifols during the fourth quarter worth about $398,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Grifols by 350.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,111 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 10,979 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of Grifols during the third quarter worth about $446,000. Finally, Sei Investments Co. grew its stake in shares of Grifols by 185.4% during the third quarter. Sei Investments Co. now owns 2,002,818 shares of the biotechnology company’s stock worth $18,306,000 after acquiring an additional 1,300,978 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft lowered Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

Grifols Trading Up 1.8 %

Shares of NASDAQ GRFS opened at $6.38 on Friday. The business’s 50 day moving average price is $6.92 and its 200 day moving average price is $8.32. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $12.15. The company has a current ratio of 2.83, a quick ratio of 1.32 and a debt-to-equity ratio of 1.24.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.